Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Multicenter, Open-label Phase IV trial of Trifluridine/Tipiracil (FTD/TPI) to Evaluate the Health-related Quality of Life in Patients with Metastatic Colorectal Cancer (mCRC)

Trial Profile

Prospective, Multicenter, Open-label Phase IV trial of Trifluridine/Tipiracil (FTD/TPI) to Evaluate the Health-related Quality of Life in Patients with Metastatic Colorectal Cancer (mCRC)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms TALLISUR
  • Sponsors Servier Deutschland
  • Most Recent Events

    • 19 Jan 2019 160 patients recruited (17 Sep 2018) as per trial design presented at the 2019 Gastrointestinal Cancers Symposium.
    • 15 Nov 2018 Planned End Date changed from 30 Aug 2019 to 31 Dec 2019.
    • 15 Nov 2018 Status changed to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top